HYLORIS PHARMACEUTIC

Pleco Therapeutics B.V. announced that it has entered into an agreement to receive ?1 million in a round of funding from new investor Hyloris Pharmaceuticals SA on November 10, 2021. Under the terms, investor will provide ?1 million automatically convertible into company?s equity under certain conditions in several tranches over time. Subject to feedback from the FDA on the feasibility of the clinical development requirements, investor may commit to fund not convertible into equity up to an additional ?7.7 million in pre-defined research and development activities through to submission for approval in AML, plus initial exploratory development work in SCLC.